Download PDF
Semin Thromb Hemost 2006; 32(8): 755-766
DOI: 10.1055/s-2006-955458
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Prevention of Venous Thromboembolism

Mario Pini1 , Alex C. Spyropoulos2
  • 1Medicina Interna II, Ospedale di Fidenza, Fidenza, Parma, Italy
  • 2Clinical Thrombosis Center, Lovelace Medical Center Albuquerque, New Mexico
Further Information

Publication History

Publication Date:
15 December 2006 (online)

    Permissions and Reprints

ABSTRACT

Patients with clinical conditions such as surgery, trauma, and acute medical illness have a transiently increased risk of venous thromboembolism and merit consideration for adequate thromboprophylaxis. The choice of an appropriate pharmacologic or physical means of prophylaxis should be made taking into account both the thrombotic and bleeding risk associated with patient-related factors and the type of surgery or other disease state involved. A large number of randomized clinical trials, meta-analyses, and guidelines developed by scientific societies worldwide have addressed this issue and have provided information and recommendations that should be considered carefully. The aim of this review is to provide the practicing physician with a brief updated summary of the subject, stratifying those patients at low thrombotic risk who do not require specific thromboprophylaxis apart from early ambulation, from those at moderate or higher thrombotic risk. Patients at moderate thrombotic risk face a 10 to 20% risk of deep vein thrombosis (DVT) and require prophylaxis with low-dose unfractionated heparin or low molecular weight heparins (LMWHs) at a dosage < 3400 U once daily, or with graduated elastic stockings if their bleeding risk is high. Patients with an expected 20 to 40% DVT rate without prophylaxis are considered at high thrombotic risk and should be treated preferentially with LMWHs at high prophylactic dosage (> 3400 U). Patients undergoing major orthopedic surgery face a DVT rate > 40%, are considered at very high risk of venous thromboembolism, and should be given either LMWHs at high prophylactic dosage, fondaparinux, or vitamin K antagonists-either alone or in association with intermittent pneumatic compression devices.

KEYWORDS

Thrombotic risk assessment - thromboprophylaxis - prophylaxis of venous thromboembolism - prevention of venous thromboembolism

REFERENCES

  • 1 Geerts W H, Pineo G F, Heit J A et al.. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 338S-400S
    CrossrefPubMedGoogle Scholar
  • 2 Gallus A S, Hirsh J, O'Brien S E, McBride J A, Tuttle R J, Gent M. Prevention of venous thromboembolism with small subcutaneous doses of heparin.  JAMA. 1976;  235 1980-1982
    CrossrefPubMedGoogle Scholar
  • 3 Kakkar V V, Corrigan T P, Fossard D P. Prevention of fatal postoperative pulmonary embolism by low dose of heparin. An international multicentre trial.  Lancet. 1975;  2 45-51
    PubMedGoogle Scholar
  • 4 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
    CrossrefPubMedGoogle Scholar
  • 5 Pini M, Froehlich J, Bergmann J F et al.. Comparison of US and European practices in the prevention of venous thromboembolism in hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE).  Blood. 2003;  11 320(Abst)
    PubMedGoogle Scholar
  • 6 Hirsh J. Low molecular weight heparin.  Thromb Haemost. 1993;  70 204-207
    PubMedGoogle Scholar
  • 7 Petitou M, Lormeau J C, Choay J. Chemical synthesis of glycosaminoglycans: new appoach to antithrombotic drugs.  Nature. 1991;  350(suppl) 30-33
    PubMedGoogle Scholar
  • 8 Eriksson B I, Bauer K A, Lassen M R et al.. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.  N Engl J Med. 2001;  345 1298-1304
    CrossrefPubMedGoogle Scholar
  • 9 Bauer K A, Eriksson B I, Lassen M R et al.. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.  N Engl J Med. 2001;  345 1305-1310
    CrossrefPubMedGoogle Scholar
  • 10 Lassen M R, Bauer K A, Eriksson B I et al.. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.  Lancet. 2002;  359 1715-1720
    CrossrefPubMedGoogle Scholar
  • 11 Turpie A G, Bauer K A, Eriksson B I et al.. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery: a randomised double blind trial.  Lancet. 2002;  359 1721-1726
    CrossrefPubMedGoogle Scholar
  • 12 Mismetti P, LaPorte S, Zufferey P, Epinat M, Decousus H, Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis.  J Thromb Haemost. 2004;  2 1058-1070
    CrossrefPubMedGoogle Scholar
  • 13 Wells P S, Lensing AWA, Hirsh J. Graduated compression stockings in the prevention of postoperative venous thromboembolism.  Arch Intern Med. 1994;  154 67-72
    CrossrefPubMedGoogle Scholar
  • 14 Amarigiri S V, Lees T A. Elastic compression stockings for prevention of deep vein thrombosis.  Cochrane Database Syst Rev. 2000;  1 , CD001484
    PubMedGoogle Scholar
  • 15 Borly L, Wille-Jørgensen P, Rasmussen M S. Systematic review of thromboprophylaxis in colorectal surgery-an update.  Colorectal Dis. 2005;  7 122-127
    CrossrefPubMedGoogle Scholar
  • 16 Muhe E. Intermittent sequential high-pressure compression of the leg: a new method of preventing deep vein thrombosis.  Am J Surg. 1984;  147 781-785
    CrossrefPubMedGoogle Scholar
  • 17 Hull R D, Raskob G E, Gent M et al.. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement.  JAMA. 1990;  263 2313-2317
    CrossrefPubMedGoogle Scholar
  • 18 Turpie A G, Hirsh J, Gent M, Julian D, Johnson J. Prevention of deep vein thrombosis in potential neurosurgical patients: a randomised trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control.  Arch Intern Med. 1989;  149 679-681
    CrossrefPubMedGoogle Scholar
  • 19 Vaughn B K, Knezevich S, Lombardi Jr A V, Mallory T H. Use of the Greenfield filter to prevent fatal embolism associated with total hip and knee arthroplasty.  J Bone Joint Surg (Am). 1989;  71 1542-1548
    PubMedGoogle Scholar
  • 20 Nicolaides A N, Bergqvist D, Hull R et al.. Prevention of venous thromboembolic events: International Consensus Statement (guidelines according to scientific evidence).  Int Angiol. 1997;  16 3-38
    PubMedGoogle Scholar
  • 21 Ageno W. Applying risk assessment models in general surgery: overview of our clinical experience.  Blood Coagul Fibrinolysis. 1999;  10(suppl) S71-S78
    PubMedGoogle Scholar
  • 22 Bergqvist D, Lindblad B, Matzsch T. Risk of combining low molecular weight heparin for thromboprophylaxis and epidural or spinal anesthesia.  Semin Thromb Hemost. 1993;  19(suppl) 147-151
    PubMedGoogle Scholar
  • 23 Wysowski D K, Talarico L, Bacsanyi J, Botstein P. Spinal and epidural haematoma and low molecular weight heparin.  N Engl J Med. 1998;  338 1774-1775
    CrossrefPubMedGoogle Scholar
  • 24 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.  N Engl J Med. 1988;  318 1162-1173
    CrossrefPubMedGoogle Scholar
  • 25 Clagett G P, Reisch J S. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis.  Ann Surg. 1988;  208 227-240
    CrossrefPubMedGoogle Scholar
  • 26 Mismetti P, Laporte S, Darmon J Y, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.  Br J Surg. 2001;  88 913-930
    CrossrefPubMedGoogle Scholar
  • 27 Nurmohamed M T, Rosendaal F R, Büller H R et al.. Low molecular weight heparin versus standard heparin in general and orthopedic surgery: a meta-analysis.  Lancet. 1992;  340 152-156
    CrossrefPubMedGoogle Scholar
  • 28 Leizorovicz A, Haugh M C, Chapuis F R, Samama M M, Boissel J P. Low molecular weight heparins in the prevention of post-operative thrombosis.  BMJ. 1992;  305 913-920
    PubMedGoogle Scholar
  • 29 Kakkar V V, Murray W J. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study.  Br J Surg. 1985;  98 266a
    PubMedGoogle Scholar
  • 30 The European Fraxiparin Study Group . Comparison of a low molecular weight and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery.  Br J Surg. 1988;  75 1058-1063
    PubMedGoogle Scholar
  • 31 Koch A, Bouges S, Ziegler S, Dinkel H, Daures J P, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical interventions: update of previous meta-analyses.  Br J Surg. 1997;  84 750-759
    CrossrefPubMedGoogle Scholar
  • 32 Bergqvist D, Burmark U S, Flordal P A et al.. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients.  Br J Surg. 1995;  82 496-501
    CrossrefPubMedGoogle Scholar
  • 33 Kakkar V V, Cohen A, Edmonson R A et al.. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group.  Lancet. 1993;  341 259-264
    CrossrefPubMedGoogle Scholar
  • 34 Bergqvist D, Agnelli G, Cohen A T et al.. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.  N Engl J Med. 2002;  346 975-980
    CrossrefPubMedGoogle Scholar
  • 35 Wille-Jørgensen P. Low dosage heparin combined with either dihydroergotamine or graduated supportive stockings. Combined prevention of thrombosis in colonic surgery.  Ugeskr Laeger. 1986;  148 501-503
    PubMedGoogle Scholar
  • 36 Wille-Jørgensen P, Hauch O, Dimo B, Christensen S W, Jensen R, Hansen B. Prophylaxis of deep venous thrombosis after acute abdominal operations.  Surg Gynecol Obstet. 1991;  172 44-48
    PubMedGoogle Scholar
  • 37 Agnelli G, Bergqvist D, Cohen A et al.. Randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus Study.  Blood. 2003;  102 13a
    PubMedGoogle Scholar
  • 38 Riber C, Alstrup N, Nymann T, Bogstad J W, Wille-Jørgensen P, Tonnesen H. Postoperative thromboembolism after day-case herniorrhaphy.  Br J Surg. 1996;  83 420-421
    PubMedGoogle Scholar
  • 39 Baca I, Schneider B, Kohler T, Misselwitz F, Zehle A, Muhe F. Prevention of venous thromboembolism in patients undergoing minimally invasive interventions and brief inpatient treatment: Results of a multicenter, prospective, randomized, controlled study with a low-molecular-weight heparin.  Chirurgia (Bucur). 1997;  68 1275-1280
    CrossrefPubMedGoogle Scholar
  • 40 Bounameaux H, Didier D, Polat O, Desmarais S, de Moerloose P, Huber O. Antithrombotic prophylaxis in patients undergoing laparoscopic cholecystectomy.  Thromb Res. 1997;  86 271-273
    CrossrefPubMedGoogle Scholar
  • 41 White R H, Zhou H, Romano P S. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures.  Thromb Haemost. 2003;  90 446-455
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP): a study on TED stockings prophylaxis and literature review.  Scand J Urol Nephrol. 2002;  36 119-123
    PubMedGoogle Scholar
  • 43 Kucher N, Koo S, Quiroz R et al.. Electronic alerts to prevent venous thromboembolism among hospitalized patients.  N Engl J Med. 2005;  352 969-977
    CrossrefPubMedGoogle Scholar
  • 44 Warwick D, Williams M H, Bannister G C. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis.  J Bone Joint Surg Br. 1995;  77 6-10
    PubMedGoogle Scholar
  • 45 Khaw F M, Moran C G, Pinder I M, Smith S R. The incidence of fatal pulmonary embolism after knee replacement with no prophylactic anticoagulation.  J Bone Joint Surg Br. 1993;  75 940-941
    PubMedGoogle Scholar
  • 46 Planes A, Vovhelle N, Mazas F et al.. Prevention of postoperative venous thrombosis: a randomised trial comparing unfractionated heparin and low molecular weight heparin in patients undergoing total hip replacement.  Thromb Haemost. 1988;  60 407-410
    PubMedGoogle Scholar
  • 47 Colwell C W, Spiro T E, Trowbridge A A et al.. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep vein thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety.  J Bone Joint Surg Am. 1994;  76 3-14
    PubMedGoogle Scholar
  • 48 Anderson D R, O'Brien B J, Levine M N, Roberts R, Wells P S, Hirsh J. Efficacy and cost of low molecular weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty.  Ann Intern Med. 1993;  119 1105-1112
    PubMedGoogle Scholar
  • 49 Leyvraz P F, Richard J, Bachmann F et al.. Adjusted versus fixed dose subcutaneous heparin in the prevention of deep vein thrombosis after total hip replacement.  N Engl J Med. 1983;  309 954-958
    CrossrefPubMedGoogle Scholar
  • 50 Hull R D, Pineo G F, MacIsaac S. Low-molecular-weight heparin prophylaxis: pre-operative versus postoperative initiation in patients undergoing elective hip surgery.  Thromb Res. 2001;  101 155-162
    CrossrefPubMedGoogle Scholar
  • 51 Eriksson B I, Lassen M R. for the PENTasacharide in Hip-FRActure Surgery Plus (PENTIPHRA PLUS) Investigators . Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.  Arch Intern Med. 2003;  163 1337-1342
    CrossrefPubMedGoogle Scholar
  • 52 Lassen M R, Borris L C, Anderson B S et al.. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-the Danish Prolonged Prophylaxis (DaPP) study.  Thromb Res. 1998;  89 281-287
    CrossrefPubMedGoogle Scholar
  • 53 Planes A, Vochelle N, Darmon J Y, Fagola M, Bellaud M, Huet Y. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo.  Lancet. 1996;  348 224-228
    CrossrefPubMedGoogle Scholar
  • 54 Bergqvist D, Benoni G, Björgell O et al.. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement.  N Engl J Med. 1996;  335 696-700
    CrossrefPubMedGoogle Scholar
  • 55 Dahl O E, Andreassen G, Aspelin T et al.. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind prospective, randomised, placebo-controlled study with dalteparin (Fragmin).  Thromb Haemost. 1997;  77 26-31
    PubMedGoogle Scholar
  • 56 Prandoni P, Bruchi O, Sabbion P et al.. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study.  Arch Intern Med. 2002;  162 1966-1971
    CrossrefPubMedGoogle Scholar
  • 57 Comp P C, Spiro T E, Friedman R J et al.. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group.  J Bone Joint Surg Am. 2001;  83 336-345
    CrossrefPubMedGoogle Scholar
  • 58 White R H, Romano P S, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty.  Arch Intern Med. 1998;  158 1525-1531
    CrossrefPubMedGoogle Scholar
  • 59 Hjelmstedt A, Bergvall U. Incidence of thrombosis in patients with tibial fractures: a phlebographic study.  Acta Chir Scand. 1968;  134 209-218
    PubMedGoogle Scholar
  • 60 Abelseth G, Buckley R E, Pineo G E, Hull R, Rose M S. Incidence of deep vein thrombosis in patients with fractures of the lower extremity distal to the hip.  J Orthop Trauma. 1996;  10 230-235
    CrossrefPubMedGoogle Scholar
  • 61 Stringer M D, Steadman C A, Hedges A R, Thomas E M, Morley T R, Kakkar V V. Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients.  J Bone Joint Surg Br. 1989;  71 492-497
    PubMedGoogle Scholar
  • 62 Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb.  Haemostasis. 1993;  23(suppl 1) 20-26
    PubMedGoogle Scholar
  • 63 Kock H J, Schmit-Neuerburg K P, Hanke J, Rudofsky G, Hirche H. Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilization of the leg.  Lancet. 1995;  346 459-461
    CrossrefPubMedGoogle Scholar
  • 64 Lassen M R, Borris L C, Nakov R L. Use of the low-molecular-weight heparin reviparin to prevent deep vein thrombosis after leg injury requiring immobilization.  N Engl J Med. 2002;  347 726-730
    CrossrefPubMedGoogle Scholar
  • 65 Jørgensen P S, Warming T, Hansen K et al.. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venographic controlled study.  Thromb Res. 2002;  105 477-480
    CrossrefPubMedGoogle Scholar
  • 66 Giannadakis K, Gehling H, Sitter H, Acherbach S, Hahne H, Gotzen L. Is a general pharmacological thromboembolism prophylaxis necessary in ambulatory treatment by plaster cast immobilization in lower limb injuries?.  Unfallchirurg. 2000;  103 475-478
    CrossrefPubMedGoogle Scholar
  • 67 Solis G, Saxby T. Incidence of DVT following surgery of the foot and ankle.  Foot Ankle Int. 2002;  23 411-414
    CrossrefPubMedGoogle Scholar
  • 68 Demers C, Marcoux S, Ginsberg J S, Laroche F, Cloutier R, Poulin J. Incidence of venographically proved deep vein thrombosis after knee arthroscopy.  Arch Intern Med. 1998;  158 47-50
    CrossrefPubMedGoogle Scholar
  • 69 Schippinger G, Wirnsberger G H, Obernosterer A, Babinski K. Thromboembolic complications after arthroscopic knee surgery. Incidence and risk factors in 111 patients.  Acta Orthop Scand. 1998;  69 144-146
    PubMedGoogle Scholar
  • 70 Jaureguito J W, Greenwald A E, Wilcox J F, Paulos L E, Rosenberg T D. The incidence of deep venous thrombosis after arthroscopic knee surgery.  Am J Sports Med. 1999;  27 707-710
    PubMedGoogle Scholar
  • 71 Wirth T, Schneider B, Misselwitz F et al.. Prevention of venous thromboembolism after knee arthroscopy with low-molecular-weight heparin (reviparin): results of a randomised controlled trial.  Arthroscopy. 2001;  17 393-399
    PubMedGoogle Scholar
  • 72 Michot M, Conen D, Holtz D et al.. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: a randomised trial of prophylaxis with low-molecular-weight heparin.  Arthroscopy. 2002;  18 257-263
    CrossrefPubMedGoogle Scholar
  • 73 Belch J J, Lowe G D, Pollock J G, Forbes C D, Prentice C R. Low dose heparin in the prevention of deep-vein thrombosis after aortic bifurcation graft surgery.  Thromb Haemost. 1980;  42 1429-1433
    PubMedGoogle Scholar
  • 74 Olin J W, Graor R A, O'Hara P, Young J R. The incidence of deep venous thrombosis in patients undergoing abdominal aortic aneurysm resection.  J Vasc Surg. 1993;  18(6) 1037-1041
    CrossrefPubMedGoogle Scholar
  • 75 Hollyoak M, Woodruff P, Muller M, Daunt N, Weir P. Deep venous thrombosis in postoperative vascular surgical patients: a frequent finding without prophylaxis.  J Vasc Surg. 2001;  34(4) 656-660
    CrossrefPubMedGoogle Scholar
  • 76 Saarinen J, Sisto T, Laurikka J, Salenius J P, Tarkka M. Late sequelae of acute deep venous thrombosis: evaluation five and ten years after.  Phlebology. 1995;  10 106-109
    PubMedGoogle Scholar
  • 77 Farkas J C, Chapuis C, Combe S et al.. A randomised controlled trial of a low-molecular-weight heparin (Enoxaparin) to prevent deep-vein thrombosis in patients undergoing vascular surgery.  Eur J Vasc Surg. 1993;  7(5) 554-560
    CrossrefPubMedGoogle Scholar
  • 78 Kudsk K A, Fabian T C, Baum S, Gold R E, Mangiante E, Voeller G. Silent deep vein thrombosis in immobilized multiple trauma patients.  Am J Surg. 1989;  158(6) 515-519
    CrossrefPubMedGoogle Scholar
  • 79 Meissner M H, Chandler W L, Elliott J S. Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability?.  J Trauma. 2003;  54(2) 224-231
    PubMedGoogle Scholar
  • 80 Geerts W H, Jay R M, Code K I et al.. A comparison of low-dose heparin with low molecular weight heparin as prophylaxis against venous thromboembolism after major trauma.  N Engl J Med. 1996;  335 701-707
    CrossrefPubMedGoogle Scholar
  • 81 Elliott C G, Dudney T M, Egger M et al.. Calf-thigh sequential pneumatic compression compared with plantar venous pneumatic compression to prevent deep-vein thrombosis after non-lower extremity trauma.  J Trauma. 1999;  47(1) 25-32
    CrossrefPubMedGoogle Scholar
  • 82 Consortium for Spinal Cord Medicine . Prevention of thromboembolism in spinal cord injury.  J Spinal Cord Med. 1997;  20(3) 259-283
    PubMedGoogle Scholar
  • 83 Cade J F. High risk of the critically ill for venous thromboembolism.  Crit Care Med. 1982;  10(7) 448-450
    CrossrefPubMedGoogle Scholar
  • 84 Belch J J, Lowe GDO, Ward A G, Forbes C D, Prentice CRM. Prevention of deep vein thrombosis in medical patients by low-dose heparin.  Scott Med J. 1981;  26 115-117
    PubMedGoogle Scholar
  • 85 Samama M M, Cohen A T, Darmon J Y et al.. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients.  N Engl J Med. 1999;  341(11) 793-800
    CrossrefPubMedGoogle Scholar
  • 86 Leizorovicz A, Cohen A T, Turpie A G, Olsson C G, Vaitkus P T, Goldhaber S Z. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.  Circulation. 2004;  110(7) 874-879
    CrossrefPubMedGoogle Scholar
  • 87 Cohen A T, Davidson B L, Gallus A S et al.. Efficacy and safety of Fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.  Br Med J. 2006;  332 325-329
    CrossrefPubMedGoogle Scholar
  • 88 Nicolaides A N, Breddin H K, Fareed J et al.. Prevention of venous thromboembolism. International Consensus Statement.  Int Angiol. 2001;  20(1) 1-37
    PubMedGoogle Scholar
  • 89 Levine M, Rickles F R. Treatment of venous thromboembolism in cancer patients.  Haemostasis. 1998;  28(suppl 3) 66-70
    CrossrefPubMedGoogle Scholar
  • 90 Alikhan R, Cohen A T, Combe S et al.. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.  Arch Intern Med. 2004;  164(9) 963-968
    CrossrefPubMedGoogle Scholar
  • 91 Samama M M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients.  Arch Intern Med. 2000;  160 3415-3420
    CrossrefPubMedGoogle Scholar
  • 92 Cohen A T, Edmondson R A, Phillips M J, Ward V P, Kakkar V V. The changing pattern of venous thromboembolic disease.  Haemostasis. 1996;  26 65-71
    PubMedGoogle Scholar
  • 93 Baglin T P, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients.  J Clin Pathol. 1997;  50 609-610
    PubMedGoogle Scholar
  • 94 Goldhaber S Z, Tapson V F. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.  Am J Cardiol. 2004;  93(2) 259-262
    CrossrefPubMedGoogle Scholar
  • 95 Tapson V F, Decousus H, Piovella F, Zotz R B, Allegrone J, Anderson F A. A multinational observational cohort study in acutely ill medical patients of practices in prevention of venous thromboembolism: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE).  Blood. 2003;  11 321a
    PubMedGoogle Scholar
  • 96 Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis.  Ann Intern Med. 1982;  96 561-565
    PubMedGoogle Scholar
  • 97 Gardlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases.  Lancet. 1996;  347 1357-1361
    CrossrefPubMedGoogle Scholar
  • 98 Lechler E, Schramm W, Flosbach C W. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin).  Haemostasis. 1996;  26(suppl 2) 49-56
    PubMedGoogle Scholar
  • 99 Kleber F X, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach C W. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.  Am Heart J. 2003;  145 614-621
    CrossrefPubMedGoogle Scholar
  • 100 Mismetti P, Laporte-Simitsidis S, Tardy B et al.. Prevention of venous thromboembolism in internal medicine with unfractionated heparin or low-molecular-weight heparins: a meta-analysis of randomized clinical trials.  Thromb Haemost. 2000;  83 14-19
    PubMedGoogle Scholar
  • 101 Alikhan R. A safety analysis of thromboprophylaxis in acute medical illness.  Thromb Haemost. 2003;  89 590-591
    PubMedGoogle Scholar
  • 102 Lloyd A C, Anderson P M, Quinlan D J, Bearne A. Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients.  Journal of Medical Economics. 2001;  4 99-113
    PubMedGoogle Scholar
  • 103 McGarry L J, Thompson D, Weinstein M C, Goldhaber S Z. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.  Am J Manag Care. 2004;  10(9) 632-642
    PubMedGoogle Scholar
  • 104 Turpie AGG, Levine M N, Hirsh J et al.. Double-blind randomised trial of Org 10172 low molecular weight heparinoid in prevention of deep vein thrombosis in thrombotic stroke.  Lancet. 1987;  1(8532) 523-526
    PubMedGoogle Scholar
  • 105 Turpie AGG. Orgaran in the prevention of deep vein thrombosis in stroke patients.  Haemostasis. 1992;  22 92-98
    PubMedGoogle Scholar
  • 106 Hillbom M, Erilä T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.  Acta Neurol Scand. 2002;  106 84-92
    CrossrefPubMedGoogle Scholar
  • 107 Muir K W, Watt A, Baxter G, Grosset D G, Lees K R. Randomized trial of graded compression stockings for prevention of deep-vein thrombosis after acute stroke.  QJM. 2000;  93(6) 359-364
    CrossrefPubMedGoogle Scholar
  • 108 Kapoor M, Kupfer Y Y, Tessler S. Subcutaneous heparin prophylaxis significantly reduces the incidence of venous thromboemolic events in the critically ill.  Crit Care Med. 1999;  27(12 suppl) A69
    PubMedGoogle Scholar
  • 109 Goldhaber S Z, Kett D H, Cusumano C J et al.. Low molecular weight heparin versus minidose unfractionated heparin for prophylaxis against venous thromboembolism in medical intensive care unit patients: a randomized controlled trial.  JACC. 2000;  35(suppl) 325A
    PubMedGoogle Scholar

Professor Mario PiniM.D. 

Medicina II, Ospedale di Fidenza

via Tencati 5, 43036 Fidenza, Parma, Italy

Email: mpini@ausl.pr.it

      >